Eli Lilly and Novo Nordisk have entered into a partnership with telehealth company Mangoceuticals to distribute their GLP‑1 weight‑loss drugs, Zepbound and Wegovy, through MangoRx Direct and PeachesRx Direct. The arrangement will use Lilly’s LillyDirect® Self‑Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy to deliver the medications directly to patients’ homes, bypassing traditional pharmacy channels.
The partnership does not disclose specific financial terms, but it will allow patients to purchase the drugs on a cash‑pay basis, with medication costs starting at $499 per month and a $99 per month membership fee for Mangoceuticals’ services. The deal aligns with a White House initiative to lower copays for GLP‑1 therapies, positioning the partnership as part of a broader effort to reduce prescription drug costs for Medicare and Medicaid beneficiaries.
Lilly’s Q3 2025 earnings—revenue of $17.60 billion, a 54% year‑over‑year increase, and a non‑GAAP EPS of $7.02—provide a strong financial backdrop for the expansion. Novo Nordisk has been distributing Wegovy through other telehealth providers such as Hims & Hers, LifeMD, and Ro, and the Mangoceuticals partnership adds another channel to its growing direct‑to‑consumer footprint.
Mangoceuticals’ financial health is precarious: a market capitalization of $20.01 million, revenue of $0.52 million with no growth over three years, and significant losses (EPS of –$3.86 and a net margin of –2,757.67 %). The partnership represents a high‑stakes opportunity for the company, as securing access to high‑demand GLP‑1 drugs could be critical to its survival and growth.
For Lilly and Novo Nordisk, the collaboration expands market penetration and supports the continued growth of their GLP‑1 therapies. By leveraging telehealth platforms, the companies can reach patients who prefer online ordering and home delivery, potentially increasing prescription uptake and adherence. The partnership also signals a competitive shift in the obesity‑treatment market, where direct‑to‑consumer access is becoming a key differentiator.
The deal illustrates the broader trend of pharmaceutical companies partnering with telehealth providers to streamline the patient journey—from virtual consultation to prescription fulfillment—while also addressing supply‑chain constraints and enhancing patient support services. The partnership’s success will hinge on Mangoceuticals’ ability to manage its financial risks and deliver reliable service at scale.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.